- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/72 - Two oxygen atoms, e.g. hydantoin
Patent holdings for IPC class C07D 233/72
Total number of patents in this class: 103
10-year publication summary
|
10
|
10
|
8
|
7
|
4
|
9
|
1
|
2
|
2
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1281 |
10 |
| Autifony Therapeutics Limited | 51 |
6 |
| sanofi-aventis | 294 |
5 |
| Takeda Pharmaceutical Company Limited | 2700 |
4 |
| Cv6 Therapeutics (NI) Limited | 33 |
4 |
| Galderma Research & Development | 351 |
3 |
| Medivation Prostate Therapeutics LLC | 16 |
3 |
| Novartis AG | 10173 |
2 |
| Sanofi-Aventis Deutschland GmbH | 2588 |
2 |
| Sumitomo Chemical Company, Limited | 8968 |
2 |
| Abbvie Inc. | 1799 |
2 |
| University of South Florida | 1903 |
2 |
| ForeSee Pharmaceuticals Co., Ltd. | 41 |
2 |
| Hinova Pharmaceuticals Inc. | 103 |
2 |
| Hydro-Quebec | 633 |
2 |
| Jiangsu Hengrui Medicine Co., Ltd. | 686 |
2 |
| Kowa Company, Ltd. | 1241 |
2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 719 |
2 |
| Sanofi | 4319 |
2 |
| Avidence Therapeutics, Inc. | 12 |
2 |
| Other owners | 42 |